Search

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

Membership

Boost your career, fast-track your development, and make new connections by joining a pioneering European hematology organization with global reach.

Read more

Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

Read more

Presentations

EHA-ISHBT Hematology Tutorial

Session 1: Congenital and acquired neutropenias and bone marrow failure  

Lecture:  F Fioredda (here)
Clinical case: F Fioredda (here)
Self-assessment cases:
Speaker 1: M Mahapatra (Permission not granted)
Speaker 2: A Khurana (here)
Session 2: Hemolytic Anemia

Lecture:  L Da Costa (Not available)
Clinical case: L…

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more